Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2021 • 79,611 citations

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Cell Signaling by Receptor Tyrosine Kinases

2010 • 7,477 citations

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

2010 • 5,874 citations

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

2006 • 4,800 citations

Comprehensive genomic characterization of head and neck squamous cell carcinomas

2015 • 3,529 citations

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 • 3,395 citations

ERBB receptors and cancer: the complexity of targeted inhibitors

2005 • 3,200 citations

Met, metastasis, motility and more

2003 • 2,526 citations

Isolation of a Mouse Submaxillary Gland Protein Accelerating Incisor Eruption and Eyelid Opening in the New-born Animal

1962 • 2,192 citations

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

2009 • 1,892 citations

Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer

2003 • 1,248 citations

Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

1998 • 1,083 citations

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

2018 • 1,039 citations

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

2005 • 1,025 citations

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

2018 • 961 citations

The quest to overcome resistance to EGFR-targeted therapies in cancer

2013 • 942 citations

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2007 • 937 citations

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

2005 • 879 citations

CXCR3 ligands: redundant, collaborative and antagonistic functions

2011 • 865 citations

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.

1987 • 843 citations

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

2018 • 823 citations

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

2003 • 803 citations

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

2014 • 767 citations

Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

2000 • 748 citations

Prognostic Significance of p16^INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

2010 • 702 citations

Epstein–Barr virus: more than 50 years old and still providing surprises

2016 • 678 citations

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

2010 • 630 citations

Oral Cancer Risk in Relation to Sexual History and Evidence of Human Papillomavirus Infection

1998 • 591 citations

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

2008 • 518 citations

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

2006 • 481 citations

Epidermal growth factor receptor targeting in cancer: A review of trends and strategies

2013 • 469 citations

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial

2011 • 456 citations

Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis

2011 • 429 citations

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

2013 • 416 citations

Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer

2007 • 391 citations

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

2009 • 373 citations

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

2015 • 361 citations

TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

2010 • 361 citations

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

2010 • 360 citations

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

2011 • 312 citations

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients

2013 • 291 citations

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

2015 • 266 citations

Signaling through cyclin D-dependent kinases

2013 • 261 citations

Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

2005 • 261 citations

Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic Antibodies

2007 • 259 citations

Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

2007 • 257 citations

Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

2005 • 236 citations

HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

2009 • 224 citations

Nuclear EGFR as a molecular target in cancer

2013 • 215 citations

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

2013 • 204 citations

Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma

2006 • 190 citations

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

2013 • 190 citations

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

2017 • 186 citations

Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck

2003 • 183 citations

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

2021 • 173 citations

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

2014 • 166 citations

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

2015 • 164 citations

The potential and promise of IL-15 in immuno-oncogenic therapies

2017 • 159 citations

Habitual Risk Factors for Head and Neck Cancer

2004 • 157 citations

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma

2010 • 154 citations

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

2015 • 153 citations

Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations

2021 • 149 citations

Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer

2007 • 143 citations

Acquired resistance to EGFR‐targeted therapies in colorectal cancer

2014 • 140 citations

Mutations of the BRAF gene in squamous cell carcinoma of the head and neck

2003 • 129 citations

Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors

2014 • 119 citations

Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients

2016 • 118 citations

Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines

2004 • 112 citations

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

2012 • 109 citations

Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs inEGFRMutant Lung Cancer

2011 • 104 citations

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

2012 • 103 citations

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

2006 • 98 citations

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation

2010 • 97 citations

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study

2015 • 91 citations

Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study

2021 • 90 citations

Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment

2011 • 90 citations

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance

2011 • 85 citations

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies

2014 • 84 citations

Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas

2011 • 83 citations

RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

2014 • 82 citations

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

2011 • 81 citations

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition

2013 • 76 citations

Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab

2016 • 73 citations

Der nukleäre EGFR als neues therapeutisches Ziel. Einsichten in die nukleäre Translokation und Funktion

2009 • 72 citations

Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy

2012 • 69 citations

Control of NK Cell Activation by Immune Checkpoint Molecules

2017 • 67 citations

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma

2016 • 67 citations

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck

2011 • 67 citations

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

2009 • 64 citations

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

2020 • 63 citations

Aurora kinases in head and neck cancer

2013 • 62 citations

Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells

2009 • 62 citations

Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer

2017 • 55 citations

Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer

2013 • 55 citations

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

2016 • 52 citations

HIF-2 -mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia

2010 • 50 citations

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

2016 • 48 citations

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

2020 • 46 citations

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

2021 • 44 citations

Targeting Aurora Kinases in Cancer Treatment

2011 • 43 citations

The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

2016 • 42 citations

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study

2021 • 41 citations

Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review

2017 • 41 citations

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

2019 • 37 citations

Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

2020 • 36 citations

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines

2012 • 35 citations

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

2013 • 34 citations

Translational up‐regulation of Aurora‐A in EGFR‐overexpressed cancer

2009 • 31 citations

Immunotherapy for Head and Neck Squamous Cell Carcinoma

2015 • 31 citations

Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer

2022 • 22 citations

Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation

2019 • 17 citations

Targeting ErbB‐1 and ErbB‐4 in irradiated head and neck cancer: Results of in vitro and in vivo studies

2012 • 13 citations

Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience

2021 • 12 citations

Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.

2016 • 4 citations

Abstract CT119: Phase II study of dasatinib in combination with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma

2016 • 1 citations